Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study

Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study

ABSTRACT Background Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, co...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jung Sun Kim, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Jung Yong Hong, Ho Yeong Lim, Han Sang Kim, Chang Gon Kim, Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	Cancer Medicine
Subjects:	advanced HCC immune checkpoint inhibitor Nivolumab monotherapy Nivolumab plus ipilimumab organ‐specific objective response rate prior ICI treatment
Online Access:	https://doi.org/10.1002/cam4.70997
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Colitis grave inmunomediada por Nivolumab-Ipilimumab: a propósito de un caso
by: Maria Victoria Foglino, et al.
Published: (2025-07-01)

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Sarcomatoid diffuse pleural mesothelioma in an 80-year-Old woman with long-term response to nivolumab plus ipilimumab: A case report
by: Yukiko Yoshida, et al.
Published: (2025-01-01)

Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
by: Tomoki Taniguchi, et al.
Published: (2024-12-01)

Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
by: Pascal Spahn, et al.
Published: (2024-12-01)

Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
by: Hiroshi Sawayama, et al.
Published: (2022-12-01)

Retreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series
by: Illaa Smesseim, MD, et al.
Published: (2025-07-01)

Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
by: Bowen Dai, et al.
Published: (2025-01-01)

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
by: Sabine Schmid, MD, et al.
Published: (2024-12-01)

Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations
by: Celeste Vallejo, et al.
Published: (2025-03-01)

Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab
by: M. Oshima, et al.
Published: (2025-03-01)

Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease
by: Hiroaki Satoh, et al.
Published: (2022-06-01)

A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)
by: I.M. Chen, et al.
Published: (2025-06-01)

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
by: Yoshihiko Tasaki, et al.
Published: (2025-01-01)

Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland
by: Artur Drobniak, et al.
Published: (2025-08-01)

Cytokine release syndrome treated with tocilizumab following ipilimumab–nivolumab combination therapy in advanced renal cell carcinoma
by: Toru Inoue, et al.
Published: (2025-01-01)

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01)

A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab
by: Atsuto Mouri, et al.
Published: (2025-04-01)

Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study
by: Toshiyuki Sumi, et al.
Published: (2025-01-01)

Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study
by: Yuhei Kurata, et al.
Published: (2025-05-01)

Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro
by: Ilaria Cosci, et al.
Published: (2025-03-01)

Combatting mucosal melanoma: recent advances and future perspectives
by: Helen Tyrrell, et al.
Published: (2018-09-01)

Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven‐Year‐Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review
by: Aziz Eghbali, et al.
Published: (2025-08-01)

Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases
by: Chika Nagahisa, et al.
Published: (2025-08-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population
by: Khor Zhong Wei, et al.
Published: (2019-03-01)

Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study
by: Alessandro Inno, et al.
Published: (2025-07-01)

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
by: Fateen Ata, et al.
Published: (2024-12-01)

Bullous pemphigoid associated with the use of nivolumab in a patient with metastatic melanoma: a case report.
by: Diego Lopes Paim Miranda, et al.
Published: (2020-01-01)

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

Nivolumab-induced interstitial lung disease in the patient with melanoma
by: Marcin Morawski, et al.
Published: (2024-02-01)

A Case of Advanced Renal Cell Carcinoma With Concomitant Development of Multiple Endocrine Neoplasia Type 1 That Affected Treatment Progress With Immunotherapy
by: Masataka Abe, et al.
Published: (2025-07-01)

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
by: Matteo Santoni, et al.
Published: (2025-05-01)

Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
by: Toshihiko Matsumoto, et al.
Published: (2025-08-01)

Two cases of Stevens-Johnson syndrome presenting severe ocular complications associated with immune checkpoint inhibitor
by: Yukiko Nakahara-Omori, et al.
Published: (2025-07-01)

Consistently Reproducible Fixed Drug-induced Urticaria in a Patient with Metastatic Melanoma Under Immunotherapy
by: Thilo Gambichler, et al.
Published: (2025-05-01)

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
by: Young Kwang Chae, et al.
Published: (2025-08-01)

Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01)

Successful treatment of recurrent metastatic nasopharyngeal carcinoma with nivolumab: a case report
by: Yu. M. Bychkov, et al.
Published: (2019-07-01)